Vanda Pharmaceuticals
VNDA
186 hedge funds and large institutions have $1.35B invested in Vanda Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 61 increasing their positions, 58 reducing their positions, and 26 closing their positions.
100% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 26
26% more call options, than puts
Call options by funds: $7.34M | Put options by funds: $5.84M
16% more funds holding
Funds holding: 160 → 186 (+26)
12% more capital invested
Capital invested by funds: $1.2B → $1.35B (+$147M)
1.42% more ownership
Funds ownership: 99.67% → 101.09% (+1.4%)
5% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 58
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$21.1M |
| 2 |
Renaissance Technologies
New York
|
+$10.9M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$10M |
| 4 |
Millennium Management
New York
|
+$6.9M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$20.7M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$11.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$9.87M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.98M |
| 5 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
-$5.94M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
201
Quantbot Technologies
New York
| – | -$80K | -3,525 | Closed |
|
|
NIT
202
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$47K | -2,035 | Closed |
|
|
GAM
203
Gemmer Asset Management
Walnut Creek,
California
| – | -$14K | -594 | Closed |
|
204
Loomis, Sayles & Company
Boston,
Massachusetts
| – | -$9K | -391 | Closed |
|
|
OWA
205
One Wealth Advisors
San Francisco,
California
| – | -$4K | -169 | Closed |
|
|
VFA
206
Valeo Financial Advisors
Carmel,
Indiana
| – | -$2K | -106 | Closed |
|
|
KF
207
Krilogy Financial
St. Louis,
Missouri
| – | -$2K | -100 | Closed |
|
|
TRCT
208
Tower Research Capital (TRC)
New York
| – | -$2K | -86 | Closed |
|
|
WSTAM
209
Wilbanks Smith & Thomas Asset Management
Norfolk,
Virginia
| – | -$1K | -60 | Closed |
|
|
JA
210
JOYN Advisors
Atlanta,
Georgia
| – | +$259 | +11 | New |
|
VNDA Hedge Fund Activity: Q4 2018 in Review
186 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2018, worth a combined $1.35B — up 12% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new VNDA positions and 26 closed out — a net gain of 26 holders — while 61 added to existing stakes and 58 trimmed.
The largest buyer was Invesco, adding an estimated $21.1M. The largest seller was Armistice Capital, exiting entirely with an estimated $20.7M sold.
- 186 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2018, up from 160 in Q3 2018.
- Funds reported $1.35B of Vanda Pharmaceuticals stock for Q4 2018, up 12% quarter-over-quarter.
- 52 funds opened new Vanda Pharmaceuticals positions in Q4 2018 and 26 closed out, a net change of +26 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2018 was Invesco, an estimated $21.1M added.
- The largest Vanda Pharmaceuticals seller in Q4 2018 was Armistice Capital, an estimated $20.7M sold.
Based on aggregated 13F filings for Q4 2018.